Latest articles
Novartis release new data on Cosentyx ® for psoriatic arthritis
Novartis releases new data on Cosentyx ® (secukinumab) from two trials of psoriatic arthritis (PsA) patients. PsA is a complex disease with multiple manifestations driving...
Mundipharma announces exclusive distribution agreement for Pelmeg▼®
Mundipharma announces exclusive distribution agreement for Pelmeg in Central and Eastern Europe. Mundipharma has entered into the exclusive distribution agreement with Egis Pharmaceuticals for Pelmeg,...
Medicines Discovery Catapult and Waters Corporation enter strategic partnership
Medicines Discovery Catapult and Waters Corporation enter strategic partnership. The partnership will give small and medium enterprises (SMEs) working with Medicines Discovery Catapult unprecedented access to...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Mundipharma announces exclusive distribution agreement for Pelmeg▼®
Mundipharma announces exclusive distribution agreement for Pelmeg in Central and Eastern Europe. Mundipharma has entered into the exclusive distribution agreement with Egis Pharmaceuticals for Pelmeg,...
Novartis presents new migraine data for Aimovig®▼ (erenumab)
Novartis presents new migraine data for Aimovig®▼ (erenumab) demonstrating sustained efficacy to 52 weeks. Novartis has announced that new data from two follow-up studies of...
What will 2D matrix coding achieve for the pharma industry?
Tony Cordrey is Vice President of European Strategic Operations at Accord Healthcare. Having been at the forefront of the Falsified Medicines Directive (FMD) rollout,...
Novartis release new data on Cosentyx ® for psoriatic arthritis
Novartis releases new data on Cosentyx ® (secukinumab) from two trials of psoriatic arthritis (PsA) patients. PsA is a complex disease with multiple manifestations driving...